- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04269681
RENOVATE Palliative: HFNC vs. Standard Respiratory Support in Patients With Do-Not-Intubate Order and ARF
Renovate Palliative Study: Randomized Controlled Trial Comparing High Flow Nasal Catheter Versus Standard Respiratory Support in Patients With Do Not Intubate Order and Acute Respiratory Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
SC
-
Florianópolis, SC, Brazil
- Hospital Nereu Ramos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants must be 18 years of age or older, with ARF of any cause on admission or post-extubation with prior DNI directives or DNI order determined in the current hospitalization.
Patients must meet the following criteria below:
- Dyspnea (defined on the Borg scale ≥4);
- SpO2 <90% or paO2 <60 mmHg in room air;
- Absence of delirium;
- One of the following:
A. Signs of respiratory distress and use of accessory muscles; B. Respiratory rate greater than 25 incursions per min .
Exclusion Criteria:
- Refusal of treatment;
- Agitation or non-cooperation;
- Presence of delirium at the time of randomization;
- Anatomical abnormalities that may interfere with the adjustment of the non-invasive positive pressure ventilation mask
- Glasgow <12;
- Psychomotor agitation that prevents adequate medical / nursing assistance requiring sedation;
- Contraindications to NIV: uncontrollable vomiting, hypersecretion of the airways, facial deformities, trauma or extensive facial burn;
- Presence of pneumothorax or extensive pleural effusion;
- Expected imminent death, defined as an estimated death of less than 24 hours.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Flow Nasal Cannula Arm
Participants will receive HFNC if they have no delirium and signs of ARF.
The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance.
There is no crossover to the standar of care arm.
|
Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher & Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature. The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea. The HFNC should be offered to the patient in ARF as follows:
Other Names:
|
Active Comparator: Standard respiratory support
Participants will receive standard of care with low flow oxygen catheter or mask initially.
If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient.
There will be no cross over with HFNC arm.
|
The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea.
For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team.
NIPPV will be performed with the patient in a supine position at 45 degrees.
The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage.
A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort.
The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dypnea
Time Frame: 48 hours
|
Variation in dyspnea according to the Borg scale in 48 hours.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 28 days
|
Mortality in 28 days
|
28 days
|
Comfort
Time Frame: 48 hours
|
Comfort measured in a visual analogue scale from 0-100
|
48 hours
|
Dose of Opioid
Time Frame: 48 hours
|
Cumulative dose of opioid
|
48 hours
|
Delirium
Time Frame: 48 hours
|
Cumulative Delirium rate measured by CAM-ICU
|
48 hours
|
Intensive Care Unit (ICU) stay
Time Frame: 28 days
|
total days inside the ICU
|
28 days
|
Usage of respiratory support devices
Time Frame: 48 hours
|
Total time in use of devices in both arms
|
48 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leticia Kawano-Dourado, MD, Hospital do Coracao
- Study Director: Alexandre B Cavalcanti, MD, Hospital do Coracao
- Principal Investigator: Lara P Kretzer, MD, HU UFSC
- Principal Investigator: Israel S Maia, MD, Hospital do Coracao
- Study Chair: Fernando Zampieri, MD, Hospital do Coracao
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IP-HCOR/RENOVATEpaliativo
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hemovent GmbHMAXIS Medical, LLCActive, not recruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory FailureGermany
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
Siriraj HospitalRecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
-
Fisher and Paykel HealthcareCentre hospitalier de l'Université de Montréal (CHUM); Institut universitaire...Not yet recruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
University Hospital, AngersNot yet recruitingCardio-Respiratory FailureFrance
-
University Hospital, MotolCompletedRefractory Respiratory FailureCzechia
Clinical Trials on High Flow Nasal Cannula
-
Aga Khan University Hospital, PakistanUnknownApneic Oxygenation
-
Hospital Clinic of BarcelonaUnknownPatient Population Submitted to ERCPSpain
-
Kuopio University HospitalCentral Finland Hospital District; Mikkeli Central Hospital; Siun soteRecruiting
-
Montefiore Medical CenterCompletedMorbid Obesity | Noninvasive Ventilation | Deep SedationUnited States
-
Samsung Medical CenterFisher and Paykel HealthcareNot yet recruitingAcute Respiratory FailureKorea, Republic of
-
Children's Hospital Los AngelesCompletedHigh Flow Nasal CannulaUnited States
-
Rush University Medical CenterHospital Civil de GuadalajaraRecruitingObesity, Morbid | Extubation FailureUnited States, Mexico
-
American University of Beirut Medical CenterRecruitingHigh-flow Nasal Cannula | Intravenous SedationLebanon
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingHypoxia | Hematologic Malignancy | Immunocompromised | Post Hematopoietic Stem Cell Transplant | Pulmonary InfiltratesCanada